Cynata Therapeutics Limited (ASX: CYP) is a clinical-stage stem cell and regenerative medicine company. Based in Australia, it aims to develop therapies based on Cymerus™. This is a proprietary therapeutic stem cell platform technology. The technology disables issues of other production methods by making use of induced pluripotent stem cells along with a precursor cell called mesenchymoangioblast. The technology helps in achieving the low-cost manufacture of cell therapy products. One such product is the mesenchymal stem cells.
On 30th May 2019, the company announced that one of its main technologies, Cymerus™ had been selected to be featured in the International Society of Cell and Gene Therapy’s Annual Meeting, scheduled for this week in Melbourne.
The ISCT meeting has more than one thousand delegates from approximately 50 countries. ISCT draws thought leaders, companies, scientists and investors in cell therapy, making it one of the top international meeting.
Professor John Rasko, AO, would be presenting the outcomes of the company’s Phase 1 clinical trial of CYP-001 for the treatment of steroid-resistant acute graft versus host disease in a plenary session on Clinical Applications of Human Pluripotent Stem Cells. Professor Rasko is the President of the ISCT.
Understanding the product better- CPY-001 has met all clinical requisites and showcased a positive safety and efficacy data to treat steroid-resistant acute GvHD in its Phase 1 trial. The company aims to advance into Phase 2 trials for GvHD, osteoarthritis and critical limb ischemia. CYP has also depicted the use of the technology in preclinical models of asthma, heart attack, diabetic wounds and cytokine release syndrome.
Professor Igor Slukvin, the company’s founder and the inventor Cymerus technology would present at a plenary satellite session on Production of iPSCs for Clinical Use. Besides him, Dr Kilian Kelly, CYP’s Chief Operating Officer, would make two presentations on development plans for the Cymerus technology.
On 20th May 2019, the company appointed Dr Geoff Brooke as its independent non-executive director to the Board. Further, Dr Suzanne Lipe was appointed as Vice President, Alliance Management. Dr Kilian Kelly was promoted to pursue a new role of CYP’s Chief Operating Officer.
Prior to this, early in March, CYP updated on the preparation and commencement of activities for its planned Phase 2 clinical trial of the Cymerus™mesenchymal stem cell product CYP-002 in patients with critical limb ischaemia. The trial protocol was at the final draft stage and had been reviewed by prime opinion leads. A leading contract research organisation focussed on the activities for the same. Trail recruitment would begin by the fourth quarter of calendar year 2019.
The below table depicts the cash flow highlights of the company for the March 2019 quarter:
Share Price Information:
As on 31st May 2019, the stock is trading at A$1.270 (as at AEST: 2:42 PM), up by 0.794% up from its previous day’s close.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.